About Careers MedBlog Contact us

Promising Trial Vaccine in China to Prevent Hand, Foot, Mouth Disease

by Thilaka Ravi on May 29, 2013 at 7:57 AM
Font : A-A+

Promising Trial Vaccine in China to Prevent Hand, Foot, Mouth Disease

A trial vaccine has provided significant protection against a virus that can cause potentially deadly hand, foot and mouth disease (HFMD) in children, researchers in China said Wednesday.

In the final testing phase, the vaccine proved 90 percent effective, providing protection for at least 12 months against HFMD caused by the enterovirus 71 (EV71), said a study published in The Lancet.


Since it was discovered in 1969, EV71 has caused major outbreaks of HFMD around the world, affecting mostly children and mainly in Asia.

HFMD caused by EV71 has caused more than 2,000 deaths out of about six million infections, mainly of children, in the past decade, said the study's authors.

It can also cause other, more severe diseases in young children, such as meningitis and encephalitis.

The candidate vaccine was tested in a trial with more than 10,000 healthy children from six to 35 months of age at four sites across China. Half of the children were given the vaccine and half a placebo.

"The vaccine was well tolerated," said a statement, and no serious side-effects were noted.

HFMD starts with fever, painful sores in the mouth, and a rash of blisters on the hands, feet and buttocks, followed in some cases by more serious neurological, cardiovascular and breathing problems.

Not to be confused with foot-and-mouth disease in cattle, sheep and pigs, HFMD is spread from person to person through direct contact.

No vaccine yet exists against the EV71 virus.

The study authors said there was no evidence their trial drug would work on coxsackievirus A16 -- a virus that often circulates with EV71 and is the main cause of HFMD, though in a milder form.

In a comment published with the study, The Lancet described the results as a "notable advance" but said it was limited in dealing exclusively with the C4 strain of EV71 which is predominant in mainland China.

It is thus not known whether the trial vaccine would also work on regionally specific strains.

"This shortcoming affects how the findings can be applied to other countries in Asia," said the journal.

"Future studies should assess serum immune responses across different genogroups."

The comment pointed out that the youngest participants in the study were vaccinated at the age of six months, leaving younger infants vulnerable to EV71 infection.

It also said that given the relatively low mortality rate from EV71 infections, the vaccine's major contribution would be to reduce hospital admissions.

"The next step is to assess the appropriateness of including an EV71 vaccine in China's national immunisation programme, including a cost-effectiveness analysis," the journal stated.

Source: AFP


Recommended Reading

Latest Clinical Trials News

 Nanorobots: A Revolutionary Tool in Targeting Fungal Infections
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
 Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
Stickers Promise a Painless Mode of Measles Vaccine Delivery
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
 New Wearable Ultrasound Device Monitors Deep-Tissues in Moving Subjects
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.
Exploring the Benefits of a Chemotherapy Regimen Following Pancreatic Cancer Surgery
Combination of chemotherapy drugs was found to show promising results in patients with pancreatic cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Promising Trial Vaccine in China to Prevent Hand, Foot, Mouth Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests